Company Overview
Aclarion, Inc. functions as a specialized healthcare technology entity within the United States, leveraging magnetic resonance spectroscopy (MRS) and proprietary biomarkers to optimize clinical treatments for its patients. The company's primary product, NOCISCAN, utilizes MRS capabilities to non-invasively analyze the chemical composition of tissues, facilitating advanced diagnostic and therapeutic monitoring without invasive procedures. Operating within the broader Healthcare sector and specifically the Health Information Services industry, Aclarion positions itself at the intersection of medical device innovation and clinical data analytics. As of the latest available data, the company maintains a market capitalization of $6.98M with an annual revenue of $67,483 and employs a workforce of 5 individuals. These financial figures indicate that Aclarion is a micro-cap entity with a very small market footprint, suggesting it is in an early-stage development phase where revenue generation is currently limited relative to its operational scope and capital requirements.
Financial Health
The company reported a revenue of $67,483 over the trailing twelve months, yet this figure stands in stark contrast to its net income of -$7,388,275 and an EBITDA of -$6,647,278. The substantial gap between the modest revenue of $67,483 and the massive net loss of -$7,388,275 reveals a highly leveraged cost structure where expenses significantly outpace income generation, a common characteristic in deep-tech healthcare startups before product maturity. Free cash flow stands at -$4,137,211, indicating that the company is currently burning cash to fund its operations and research, which severely limits its immediate financial flexibility and reliance on external capital sources. Margin analysis shows a Gross Margin of -7.8%, an Operating Margin of -9666.2%, and a Profit Margin of 0.0%, collectively signaling that the company's current business model is not yet profitable at a scale that covers its overhead or costs of goods sold. The balance sheet holds $11.38M in cash against N/A for total debt, with a debt-to-equity ratio listed as N/A, suggesting a conservative approach to leverage despite the significant operational losses. This liquidity position is further underscored by a Current Ratio of 17.01, which indicates an extremely robust ability to meet short-term obligations with its liquid assets. However, the Return on Equity of -97.7% and Return on Assets of -52.4% reveal that management has not yet achieved effective capital deployment to generate positive returns for shareholders or utilize assets efficiently.
Valuation Assessment
Valuation metrics for Aclarion present a complex picture given its lack of consistent profitability, with a P/E Ratio (TTM) listed as N/A and a Forward P/E of -0.22. The discrepancy between the unavailable trailing P/E and the negative forward P/E implies that the market is pricing in future earnings that must improve significantly from the current deficit state to achieve positive multiples. The Price to Book ratio is recorded at 0.14, indicating that the market values the company at a fraction of its book value, which often suggests that investors perceive the intangible assets or future potential to outweigh current book value, or conversely, that the current book value includes assets that are not easily liquidatable. Alternative valuation metrics such as a Price to Sales of 103.49 and an EV/EBITDA of 1.38 suggest that the market is willing to pay a high multiple relative to sales despite the lack of earnings, potentially reflecting high expectations for the NOCISCAN technology to capture significant market share. The stock trades between a 52-Week High of $21.33 and a 52-Week Low of $2.34, placing the current valuation within a wide volatility range that reflects the high risk associated with pre-profitable biotech stocks. The Beta of 1.44 indicates that the stock's price volatility is 44% higher than the broader market, confirming that ACON is a high-beta asset subject to significant swings based on sector sentiment and clinical trial outcomes.
Growth & Income
Revenue Growth (YoY) is reported at 31.5%, while Earnings Growth (YoY) is N/A, highlighting a scenario where top-line expansion is occurring without the corresponding bottom-line improvement necessary to drive earnings growth. The absence of earnings growth data alongside positive revenue growth implies that the company is still in an investment phase where scaling revenue does not yet translate to profitability due to the high fixed costs inherent in healthcare technology development. As a non-dividend payer with a Dividend Yield of N/A and a Payout Ratio of 0.0%, Aclarion retains all of its earnings to reinvest into research, development, and commercialization efforts rather than distributing cash to shareholders. This reinvestment strategy is typical for companies with a Profit Margin of 0.0% that prioritize long-term technological advancement over immediate income distribution to maintain a competitive edge in the health information services sector. The overall growth and income profile is characterized by rapid revenue expansion coupled with significant cash burn and a complete absence of dividend income, positioning the company as a pure-play growth vehicle reliant on future clinical success to alter its financial trajectory.